- I have read in draft the speech of my noble and learned friend Lord Hoffmann. For the reasons which he gives, I too would dismiss the appeal.
- I have had the advantage of reading in draft the speech of my noble and learned friend Lord Hoffmann. For the reasons he gives, I too would dismiss the appeal.
- I have read in draft the speech of my noble and learned friend Lord Hoffmann and for the reasons which he gives, I too would dismiss the appeal.
- I have had the advantage of reading in draft the speech of my noble and learned friend Lord Hoffmann and for the reasons which he gives, I too would dismiss the appeal.
- Merrell Dow Pharmaceuticals Inc is a U.S. company with a U.K. subsidiary. I shall call them both "Merrell Dow". About 25 years ago Merrell Dow discovered an anti-histamine drug called terfenadine. It is used by people who suffer from hay fever and similar allergies and has the advantage that, unlike some other anti-histamines, it does not have the side-effect of making one drowsy. In 1972 Merrell Dow obtained a patent for terfenadine in the United Kingdom. After a period of extension under the Patents Act 1977, it finally expired in December 1992. Other pharmaceutical companies then started to make and market terfenadine.
- In these proceedings Merrell Dow claim that their monopoly in terfenadine continues by virtue of a later patent which still has another 5 years to run. It was obtained in the following circumstances. After they had patented terfenadine, they did some research into the way it worked. They found that it passed through the stomach to be absorbed in the small intestine and was then 99.5% metabolised in the liver. This was why it had no side-effects. They analysed the chemical composition of the acid metabolite formed in the liver. Its chemical name is 4-[4-(4-hydroxydiphenylmethyl-l-piperidinyl)-l-hydroxybutyl]-∝∝-dimethylbenzeneacetic acid, but I shall call it the acid metabolite. No one had identified it before. So they patented the acid metabolite as claim 24 of a patent granted in 1980 for a number of related anti-histamine products. This is the patent in suit.
- A patent for a product is infringed by anyone who makes the product without the consent of the proprietor: see section 60(l)(a) of the Act of 1977. Merrell Dow's research, which they made public at a symposium in Strasbourg in January 1982, showed that one cannot swallow terfenadine without shortly afterwards making the acid metabolite in one's liver. This…
| MERRELL DOW PHARMACEUTICALS INC AND OTHERS | (APPELLANTS) | |
| v | ||
| H.N. NORTON & CO. LIMITED | (RESPONDENTS) | |
| AND ONE OTHER ACTION |
Lord Jauncey of Tullichettle
Lord Browne-Wilkinson
Lord Mustill
Lord Lloyd of Berwick
Lord Hoffmann
LORD JAUNCEY OF TULLICHETTLE
My Lords,
LORD BROWNE-WILKINSON
My Lords,
LORD MUSTILL
My Lords,
LORD LLOYD OF BERWICK
My Lords,
LORD HOFFMANN
My Lords,
1. The Patent in Suit
2. The Claim for Infringement
Keep reading for free
Create a free CaseChat account to read Merrell Dow Pharmaceuticals Inc v HN Norton & Co Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [1995] UKHL 14
- Decision Date
CaseChat Overview and Summary
AI summary not yet generated for this case.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.